✦ LIBER ✦

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

✍ Scribed by Inese Cebere; Lucy Dorrell; Helen McShane; Alison Simmons; Sheena McCormack; Claudia Schmidt; Carol Smith; Mary Brooks; Joanna E. Roberts; Simon C. Darwin; Patricia E. Fast; Christopher Conlon; Sarah Rowland-Jones; Andrew J. McMichael; Tomáš Hanke

Book ID: 116958363
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 289 KB
Volume: 24
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2005.08.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of a modified

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

✍ Felipe García; Juan Carlos López Bernaldo de Quirós; Carmen E. Gómez; Beatriz Pe 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 533 KB

Lessons from IAVI-006, a Phase I clinica

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 498 KB

Corrigendum to “Lessons from IAVI-006, a

Corrigendum to “Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers” [Vaccine 26 (2008) 6671–6677]

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 91 KB